Tuesday, March 5, 2013

Apixaban Featured in the New England Journal of Medicine

The FDA approved apixaban in December 2012 with an indication of reducing the risk of stroke and dangerous blood clots (systemic embolism) in patients with non-valvular atrial fibrillation in the United States.

The AMPLIFY trial, conducted by Kevin Cannon, MD and his team at PMG Research of Wilmington, was featured in the New England Journal of Medicine on February 23, 2013.

Apixaban is a new treatment option for reducing the risk of stroke.

Thank you and congratulations to the volunteers who contributed to the development of this new medication for stroke prevention through their participation in this clinical research study.

Be sure to
click here to read the New England Journal of Medicine article.


  1. I am glad to hear that clinical trials on atrial fibrillation have lead to the approval of a new type of medication which could help prevent strokes. It was not too long ago that I read an article which suggested that the average age of stroke patients was younger now that it was at the turn of the millennium.

    1. I just wanted to say thanks for sharing the information on atrial fibrillation clinical trials. I also wanted to say that research has shown that the average age of stroke patients has decreased in recent years. I am not sure how many people are aware of this, but it is certainly that we continue to work on better methods of preventing strokes.

    2. Thank you for your comment Robert! We appreciate the link to the article regarding the age of stroke patients decreasing... we will definitely share! Continuing research for Atrial Fibrilation is taking place and it will be wonderful to have potential new therapies available as an option for treatment.

  2. Steve: Thanks for your comment- very interesting statistic about stroke patients. We're excited about drug development for Atrial Fibrillation- there are many potential new therapies out there- so stay tuned!

  3. OriginalArticlefromTheNewEnglandJournalofMedicineApixaban for Extended Treatment of Venous Thromboembolism. student research journal

  4. Thank you for sharing Albina. We appreciate you taking the time to read our blog!

  5. Hello, I just wanted to say thanks for sharing this information. I think this is a very valuable option to provide for people especially now. Did you know that there was a study from last year which showed that a potential link between alcohol consumption and atrial fibrillation? With heart problems posing such a serious threat for so many people, I can only see medicine like this becoming even more invaluable.


Subscribe Via Email